Long-Term Liabilities: The sum of all non-current liabilities.
AN2 Therapeutics, Inc. (ANTX) had Long-Term Liabilities of $0.17M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.71M |
|
-- |
|
-- |
|
$9.32M |
|
$-9.32M |
|
$0.61M |
|
$-8.71M |
|
$-8.71M |
|
$-8.71M |
|
$-8.71M |
|
$-8.71M |
|
$-8.71M |
|
$-9.32M |
|
$-9.43M |
|
30.22M |
|
30.22M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$59.94M |
|
-- |
|
$2.01M |
|
$61.95M |
|
$8.72M |
|
-- |
|
|
Long-Term Liabilities |
$0.17M |
$8.89M |
|
$53.06M |
|
$53.06M |
|
$53.06M |
|
27.41M |
|
| Cash Flow Statement Financials | |
$-29.83M |
|
$28.31M |
|
$0.11M |
|
$21.35M |
|
$19.94M |
|
$-1.41M |
|
$6.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.42% |
|
-16.42% |
|
-14.06% |
|
-16.42% |
|
$1.94 |
|
$-0.99 |
|
$-0.99 |
|